NeoGenomics, Inc. (NASDAQ:NEO) has earned an average rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $10.33.

Several brokerages have recently issued reports on NEO. BidaskClub raised shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. ValuEngine raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. BTIG Research cut shares of NeoGenomics from a “buy” rating to a “neutral” rating in a research note on Monday, September 11th. Finally, Gabelli began coverage on shares of NeoGenomics in a research note on Thursday, August 24th. They set a “buy” rating and a $9.00 price objective for the company.

In other NeoGenomics news, Director Alison L. Hannah bought 20,000 shares of NeoGenomics stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average price of $9.19 per share, for a total transaction of $183,800.00. Following the acquisition, the director now owns 38,782 shares of the company’s stock, valued at approximately $356,406.58. The acquisition was disclosed in a filing with the SEC, which is available at this link. 12.20% of the stock is owned by insiders.

Several large investors have recently bought and sold shares of NEO. Janus Henderson Group PLC acquired a new position in shares of NeoGenomics during the 2nd quarter valued at $20,651,000. Janus Capital Management LLC acquired a new position in shares of NeoGenomics during the 1st quarter valued at $13,279,000. Falcon Point Capital LLC lifted its holdings in shares of NeoGenomics by 338.6% during the 2nd quarter. Falcon Point Capital LLC now owns 1,100,474 shares of the medical research company’s stock valued at $9,860,000 after acquiring an additional 849,589 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of NeoGenomics by 66.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,996,710 shares of the medical research company’s stock valued at $17,891,000 after acquiring an additional 794,281 shares in the last quarter. Finally, Granite Investment Partners LLC lifted its holdings in shares of NeoGenomics by 52.4% during the 2nd quarter. Granite Investment Partners LLC now owns 1,976,020 shares of the medical research company’s stock valued at $17,706,000 after acquiring an additional 679,778 shares in the last quarter. Institutional investors and hedge funds own 80.41% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/28/neogenomics-inc-neo-receives-10-33-consensus-target-price-from-brokerages.html.

NeoGenomics (NASDAQ:NEO) traded down 0.72% on Friday, reaching $11.10. The company’s stock had a trading volume of 54,824 shares. The stock’s market capitalization is $881.21 million. NeoGenomics has a 52 week low of $6.90 and a 52 week high of $11.63. The firm has a 50 day moving average price of $9.78 and a 200 day moving average price of $8.56.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, July 25th. The medical research company reported $0.04 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.03. NeoGenomics had a negative net margin of 2.81% and a positive return on equity of 6.09%. The firm had revenue of $66.09 million during the quarter, compared to analysts’ expectations of $62.95 million. During the same period in the previous year, the company earned $0.04 EPS. NeoGenomics’s revenue for the quarter was up 4.7% on a year-over-year basis. On average, equities analysts anticipate that NeoGenomics will post $0.18 EPS for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Stock Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related stocks with our FREE daily email newsletter.